Clinical Trial

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Name: Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC — clinical trial record (NCT07742332)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.

Trial Details

NCT Number	NCT07742332
Lead Sponsor	Peng Zhang
Conditions	EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy, Chemotherapy
Enrollment	160 participants
Start Date	2025-11-25
Primary Completion	2027-11-25 (estimated)
Study Completion	2032-11-25 (estimated)
Updated on ClinicalTrials.gov	2026-08-03